CHNG

ANALYST NOTE: CHNG (Change Healthcare Inc.) Date: 2026-06-13 Current Price: $27.49

1. Structural Readiness

State: Context-Only Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: N/A (Current price is not at a defined entry trigger) Breakout Level: Not yet defined Current Price: $27.49 Extension: N/A ATR Current: 1.0% (Sub-threshold volatility)

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None named at this date.

There is no named macro or secular thesis attached to CHNG as of 2026-06-13. This is a tactical, setup-led name. Conviction must be derived strictly from the quality of the technical setup (once defined) and the underlying business fundamentals, rather than a broader thematic tailwind. The absence of a named thesis requires a rigorous, evidence-based assessment of the company's operational execution and financial health.

3. Business Overview

Company Profile: Change Healthcare Inc. is an autonomous digital health solutions provider. It harnesses data and advanced analytics to optimize clinical processes, streamline financial operations, enhance administrative efficiency, and foster patient involvement within the American healthcare landscape.

Business Model & Segments: The company organizes its activities into three core segments:

• Software and Analytics: Delivers advanced software and analytics across revenue cycle management, provider network administration, payment precision, clinical decision support, value-based care facilitation, consumer engagement, risk adjustment, quality performance metrics, and imaging/clinical workflow optimization.
• Network Solutions: Provides comprehensive connectivity and transactional platforms facilitating financial, administrative, clinical, and pharmacy exchanges. This includes connected consumer health, network infrastructure, electronic payment solutions, data management, pharmacy services, and the aggregation/analysis of clinical and financial information.
• Technology-Enabled Services: Offers managed services covering financial and administrative oversight, value-based care programs, communication/payment systems, pharmacy benefits administration, and specialized healthcare consulting.

Clientele: The diverse client base spans healthcare payers (commercial, private, BlueCross Blue Shield, Medicare/Medicaid, provider-sponsored plans, TPAs) and providers (hospitals, health systems, physician/dental practices, pharmacies, skilled nursing, home health, telehealth, senior care, laboratories).

Historical Evidence (Source Date: 2022-08-06): While the current date is 2026, the available evidence base relies on statements made in August 2022 regarding the company's trajectory post-merger and post-pandemic:

• Growth Expectations: Management stated, "As the combined year-over-year challenges from COVID-related volumes and the UHG merger-related attrition start to subside in the third quarter, we expect significantly stronger growth starting in the fourth quarter and throughout our next fiscal year, starting in April 2023."
• Revenue Guidance: "Our expectation of 2% to 4% solutions revenue growth is unchanged from what we outlined last quarter."
• Cash Flow: "Our full year free cash flow expectation of $450 million to $500 million remains the same, albeit most likely at the lower end of the range due to the higher litigation costs associated with the merger."
• New Bookings: "Q1 was a strong new bookings quarter, particularly in our pharmacy network business, where we signed several multimillion dollar deals, including a deal worth nearly $5 million annually with an innovative technology company focused on reducing wasteful pharmacy and patient spending."
• Strategic Deals: "In Q1, we signed a medical record retrieval and clinical review deal worth over $5 million annually with one of the largest managed care organizations in the country."

4. Archetype and Conviction

Archetype: Growth Leader Fit Analysis: The company fits the "Growth Leader" archetype based on its focus on high-ROI solutions, data/AI models, and workflow capabilities. The evidence highlights a transition from post-merger/Covid headwinds to a period of "significantly stronger growth" and "strong new bookings."

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Moderate. The evidence base is anchored in 2022 transcripts. While the company profile confirms the three-segment structure in 2026, there is a significant gap in recent financial performance data (2023–2026) to confirm if the 2022 guidance was met or exceeded.
• Rerating Potential: Dependent on the realization of the 2022 growth guidance and the resolution of litigation costs mentioned in the 2022 transcript.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Evidence of sustained revenue decline or failure to meet the 2%–4% solutions revenue growth guidance originally set in 2022.
• Escalation of litigation costs beyond the "lower end of the range" ($450M–$500M FCF) projected in 2022, eroding free cash flow.

What Would Strengthen:

• New earnings data (post-2022) confirming the "significantly stronger growth" trajectory and successful integration of the UHG merger.
• Continued signing of multimillion-dollar deals in the pharmacy network and clinical review segments.

Evidence Gaps:

• Critical Missing Data: There is no evidence provided for the period between 2022 and 2026. We do not know if the 2022 guidance was met, if the "stronger growth" materialized, or if the company has faced new headwinds.
• Valuation Context: No current P/E, EV/EBITDA, or DCF metrics are available to assess if the $27.49 price is attractive relative to earnings.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Company is a Growth Leader with a defined three-segment business model; 2022 guidance indicated a path to stronger growth and $450M-$500M FCF; current price is $27.49 with sub-threshold volatility. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs and recent financials are reviewed. Expected path: Management expectations from 2022 suggest growth acceleration post-merger; structural implication is a potential re-rating if growth targets are met, but current data is insufficient to confirm. Expected horizon: Indefinite until technical setup confirms or new financial data is released.